Lantus and Cancer

Specifically, the possible relationship with cancer focused on the use of the so -called Glargina insulin, which Sanofi Aventis markets in Spain with the name of 'Lantus', and, waiting to obtain scientific evidence about these statements, the thirst asks forThe patients with type 2 diabetes who receive such treatment that "do not abandon or change it to others by their own decision."

"It is necessary not to rush into decision making and waitcausality ".

According to SED, the four observational studies published in the electronic version of 'Diabetology' last Friday, June 26 are based on computerized health records from Germany, Sweden, Scotland and the United Kingdom that "are exposed to biases or systematic confusion errors, of selection and information), some difficult adjustment such as confusion biases by indication. "

Likewise, the European Medicines Agency (EMEA, according to its acronym in English) has made public a note pointing out that in two studies-realized in Scotland and Sweden-an association has been observed between the diagnosis of breast cancer and use in use inGlargine insulin monotherapy although, however, such an increase in patients who used this insulin analogue with other types of insulin was not detected.

In these cases, this association with other types of cancers was not observed, although the relationship between the appearance of tumors and the insulin dose used was not analyzed.In another study in Germany, a dependent dose association was observed between the use of insulin glargine and the diagnosis of cancer, although there is no information about the types of cancers studied.